Latest action: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Requires drug manufacturers to show the real cost of prescription medicines to consumers.
The problem
Americans pay high prices for prescription drugs without understanding total costs. Drug pricing lacks transparency, making it hard for patients to know actual expenses.
The proposal
The bill mandates pharmaceutical companies disclose net effective costs of drugs. It aims to increase price transparency in the prescription drug market.
The impact
Patients, drug manufacturers, and insurers affected. Patients gain price information; manufacturers face disclosure requirements; insurers' negotiations may change.
Patients and doctors would see true drug costs upfront. This helps people make informed healthcare choices. Transparency can reduce surprises from medical bills.
Clear pricing lets patients compare drug options based on actual costs. Consumers can discuss affordability with doctors. Better information supports smarter medical decisions.
Transparent pricing encourages drug makers to compete on price. Companies may lower costs when prices are public. Competition can benefit consumers through lower expenses.
Insurance companies and government programs gain leverage in price talks. Knowing actual costs helps negotiators demand better deals. Transparency strengthens buyers' bargaining power.
Drug companies must invest in new reporting systems and compliance teams. These expenses may increase operational costs. Companies might pass some costs to consumers.
Manufacturers may view pricing details as trade secrets. Companies could argue disclosure harms business competition. Balancing transparency and business privacy is difficult.
Transparency alone may not lower drug prices significantly. Without price controls, disclosure doesn't force cost reductions. Knowing prices doesn't solve affordability if costs remain high.
Defining "net effective cost" requires clear rules and oversight. Different drug types and payment structures complicate calculations. Enforcement could be difficult and costly.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
No donor data found for current cycle
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.